Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F25%3A00642480" target="_blank" >RIV/68081707:_____/25:00642480 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/25:00143369 RIV/61989592:15310/25:73632644
Result on the web
<a href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01858" target="_blank" >https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01858</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1021/acs.jmedchem.5c01858" target="_blank" >10.1021/acs.jmedchem.5c01858</a>

Result language
angličtina
Original language name
Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models
Original language description
A new class of multiaction Pt(IV) prodrugs incorporating cisplatin or oxaliplatin and ALK inhibitors combine cytotoxic, anti-invasive, and immune-activating properties, supporting Pt(IV)-kinase inhibitor conjugates as a potential strategy for targeted cancer chemotherapy.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10401 - Organic chemistry

Project
<a href="/en/project/GA23-06307S" target="_blank" >GA23-06307S: Metal-based compounds as candidates for antimetastatic chemotherapy</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)